{"entity":{"id":"idea-reg-mutual-recognition-inspections-atmp","kind":"idea","name":"Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants","aka":[],"tldr":"Factories making living or radioactive cancer medicines are inspected separately by each country. Accepting each other's inspections would free up inspectors and speed supply.","summary":"The EU-US Mutual Recognition Agreement covers inspections of most human medicines but has been slow to extend to advanced therapy medicinal products and has no equivalent with Japan, China or India for these classes. Cell-therapy and radiopharmaceutical sites face repeated inspections by multiple agencies, each a multi-week interruption. The proposal is to extend PIC/S and MRA reliance explicitly to ATMP and radiopharmaceutical manufacturing, with a shared inspection schedule and a common inspection report template.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis","url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-regulatory-fragmentation","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Extending mutual recognition reduces the number of inspections per ATMP site per year by at least half and shortens the time from site readiness to multi-region supply by six months or more, with no increase in critical GMP findings.","rationale":"GMP standards for ATMPs are already largely harmonised through PIC/S Annex 2A. Duplicate inspections find the same things; the cost is capacity that could inspect new sites instead.","test":"Pilot mutual recognition for ten ATMP and radiopharmaceutical sites between FDA, EMA and MHRA, tracking inspection counts, findings and time-to-supply against matched non-participating sites.","maturity":"early-clinical","actor":"regulator","cost":"small","horizonYears":3},"route":"/ideas/idea-reg-mutual-recognition-inspections-atmp/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}]}}